SLC29A1 and cancer: Moreover, the dose-dependent reduction in gemcitabine transport following exposure of cancer cells and PSCs to the hENT1 inhibitor NBMPR, as well as the reduced gemcitabine transport following the knockdown of hENT1 in cancer cells, support the importance of hENT1 as the prime cellular transporter of gemcitabine in both cell types.